dbd-observed-penicillins-57.html
DANMAP 2015 3D
58 / 144
danmap
2015
58 antimicrobial consumption in humans 5. atc group (a) therapeutic group year 2006 2007 2008(b) 2009 2010 2011 2012 2013 2014 2015 j01aa tetracyclines 1.67 2.59 3.19 3.63 3.55 3.66 5.15 4.97 5.37 5.65 j01ca penicillins
with extended spectrum 55.13 55.39 57.18 53.76 47.46 44.77 48.60 47.90 50.95 51.75 j01ce beta-lactamase sensitive penicillins 45.26 44.55 40.90 34.61 30.83 28.98 33.04 33.13 32.03 30.52 j01cf beta-lactamase resistant penicillins 27.60 27.64 27.89 25.86 25.04 22.71 27.30 29.64 29.73 29.82 j01cr comb. of penicillins. incl. beta-lactamase inhibitors 7.77 12.17 16.37 19.74 23.15 26.47 39.14 44.60 49.81 54.14 j01db first-generation cephalosporins 0.60 0.55 0.72 0.46 0.43 0.41 0.40 0.37 0.20 0.13 j01dc second-generation cephalosporins 39.76 50.81 54.55 55.12 52.65 50.19 46.17 40.27 36.29 31.53 j01dd third-generation cephalosporins 3.53 4.24 5.10 4.98 4.10 4.33 3.50 3.53 3.18 3.22 j01df monobactams 0.00 0.18 0.27 0.21 0.29 0.60 0.48 0.45 0.19 0.08 j01dh carbapenems 5.86 8.78 11.08 11.01 13.07 12.55 12.60 13.14 12.70 12.50 j01ea trimethoprim and derivatives
1.78 1.81 1.80 1.56 1.17 1.11 1.23 1.33 1.62 1.40 j01eb short-acting sulfonamides 3.18 1.41 1.43 1.21 1.09 0.78 0.63 0.62 0.55 0.46 j01ee comb. of sulfonamides and trimethoprim. incl. derivatives 8.98 6.28 7.98 7.96 9.88 12.79 10.87 13.76 14.53 15.32 j01fa macrolides 12.01 12.70 12.53 11.97 11.45 11.47 11.61 11.08 12.04 13.90 j01ff lincosamides 1.31 1.46 1.69 1.74 1.52 1.63 2.01 2.09 2.03 1.75 j01gb aminoglycosides 7.68 7.39 6.71 5.45 5.56 5.95 6.99 6.97 5.01 5.11 j01ma fluoroquinolones 28.58 33.66 39.04 37.45 33.92 33.30 32.67 31.96 30.69 28.28 j01xa glycopeptides 2.38 2.61 2.77 3.48 3.47 3.87 4.20 4.22 3.58 3.25 j01xb polymyxins 0.53 0.22 0.21 0.24 0.32 0.28 0.30 0.54 0.85 0.77 j01xc steroid antibacterials (fusidic acid) 1.19 1.17 1.05 1.09 1.12 0.85 0.76 0.71 0.71 0.50 j01xd imidazole derivatives 11.81 10.83 13.39 13.43 12.76 13.03 13.55 13.33 13.93 12.93 j01xe nitrofuran derivatives (nitrofurantoin) 1.24 1.17 1.19 1.27 1.01 1.02 1.12 1.25 1.13 0.98 j01xx05 methenamine 0.46 0.38 0.43 0.31 0.27 0.32 0.28 0.30 0.22 0.29 j01xx08 linezolid 0.86 0.68 0.84 0.76 0.72 0.99 1.04 1.14 1.05 1.31 j01xx09 daptomycin 0.00 0.03 0.06 0.06 0.07 0.05 0.06 0.07 0.10 0.12 p01ab01 nitroimidazole derivatives (metronidazole) 9.02 9.10 9.99 10.20 9.72 9.70 9.44 8.83 7.72 6.24 a07aa09 intestinal antiinfectives (vancomycin) 8.95 9.10 9.96 10.20 9.73 9.71 9.54 9.00 7.92 1.43 j01 antibacterial agents for systemic use (total) 287.1 306.9 328.3 317.8 304.3 301.9 322.7 325.2 324.1 313.38 table 5.6. consumption of antimicrobial agents for systemic use in somatic hospitals (ddd/100 admitted patients), denmark a) from the 2015 edition of the anatomical therapeutic chemical (atc) classification system b) the number of admissions was affectedly low in 2008 due to a major hospital strike danmap 2015 figure 5.14. total somatic hospital consumption (dbd) by leading groups of antimicrobial agents (j01), denmark danmap 2015 fig 5.11 0 10 20 30 40 50 60 70 80 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ddd/100 occupied bed -days combinations of penicillins, incl. beta-lactamase inhibitors (j01cr) cephalosporins (j01db, dc, dd) carbapenems (j01dh) fluoroquinolones (j01ma) aminoglycosides (j01gb) macrolides (j01fa) beta-lactamase sensitive penicillins (j01ce) penicillins with extended spectrum (j01ca) 0 10 20 30 40 50 60 70 80 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ddd/100 occupied bed -days combinations of penicillins, incl. beta-lactamase inhibitors (j01cr) cephalosporins (j01db, dc, dd) carbapenems (j01dh) fluoroquinolones (j01ma) aminoglycosides (j01gb) macrolides (j01fa) beta-lactamase sensitive penicillins (j01ce) penicillins with extended spectrum (j01ca)
consumption-observed-hospital-59.html
